← back to search

David Gottlieb

The University of Sydney · AU
🔎 Find collaborators in Computational Mechanics · Hematology →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Computational Mechanics · Hematology
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, Cytomegalovirus and herpesvirus research, Computational Fluid Dynamics and Aerodynamics, and CAR-T cell therapy research.
h-index
82
citations
35,702
works
889
NIH funding
primary concept
email

Recent publications

Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR-T Cell Recipients-PART 2: Antiviral Therapy and Virus-Specific T Cell Therapy for HCMV in Allo-HSCT.
2026cited by 0position: contributordoi
Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR T Cell Recipients - PART 1: Risk Factors, Clinical Impact and Immune Response.
2026cited by 0position: contributordoi
Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin
New England Journal of Medicine 2025cited by 47position: middledoi
Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin.
2025cited by 32position: contributordoi
Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial.
2025cited by 7position: contributordoi
Emerging concepts of CMV in transplantation.
2025cited by 3position: contributordoi
HAT-PCR Enables Sensitive Quantification of Minimal Residual Disease in Chronic Lymphocytic Leukemia and Myeloma.
2025cited by 1position: contributordoi
Outcomes of allogeneic haemopoietic transplant for chronic lymphocytic leukaemia in the modern era.
2025cited by 1position: contributordoi
Impact of lenalidomide consolidation on health-related quality of life in chronic lymphocytic leukemia: ancillary study of the phase III CLL6-RESIDUUM trial.
2025cited by 0position: contributordoi
Expression of Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) on Malignant but Not Normal Plasma Cells Offers Novel Therapeutic Targets for Patients With Myeloma, Amyloidosis and Other Plasma Cell Dyscrasias.
2025cited by 0position: contributordoi
Human herpesvirus 6 viremia and encephalitis in CAR T-cell recipients.
2025cited by 0position: contributordoi
Mortality Is Increased in Those with a ≥10% Reduction in Spirometry Following Allogeneic Hematopoietic Stem Cell Transplant: A Retrospective 5-Year Follow-up Study from a Single Transplant Service.
2025cited by 0position: contributordoi
Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with Acute Myeloid Leukemia and Myelodysplastic Syndromes Demonstrates Long Term Survival, Results from Australia and New Zealand Transplant and Cellular Therapies.
2024cited by 2position: contributordoi
Outcomes of Allogeneic Haematopoietic Transplant for Chronic Lymphocytic Leukaemia in the Modern Era
2024cited by 0position: contributordoi
CAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies
Nature Communications 2023cited by 33position: middledoi
CAR<sup>+</sup> and CAR<sup>-</sup> T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies.
2023cited by 30position: contributordoi
Predictors of post traumatic growth in allogeneic hematopoietic stem cell transplantation survivors: a cross-sectional survey.
2023cited by 8position: contributordoi
Predictors of post traumatic growth in allogeneic hematopoietic stem cell transplantation survivors: a cross-sectional survey
BMC Psychology 2023cited by 7position: middledoi
Persistence of ex vivo expanded tumour and pathogen specific T-cells after allogeneic stem cell transplant for myeloid malignancies (the INTACT study).
2023cited by 5position: contributordoi
Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group
Heliyon 2023cited by 5position: middledoi
Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T-cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant.
2023cited by 4position: contributordoi
Early cessation of calcineurin inhibitors is feasible post-haploidentical blood stem cell transplant: the ANZHIT 1 study.
2023cited by 4position: contributordoi
Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group.
2023cited by 4position: contributordoi
Decisional Regret in Long-Term Australian Allogeneic Hematopoietic Stem Cell Transplantation Survivors: A Cross-Sectional Survey
Clinical Nursing Research 2023cited by 4position: middledoi
Decisional Regret in Long-Term Australian Allogeneic Hematopoietic Stem Cell Transplantation Survivors: A Cross-Sectional Survey.
2023cited by 3position: contributordoi
Circulating cytokine and chemokine patterns associated with cytomegalovirus reactivation after stem cell transplantation.
2023cited by 1position: contributordoi
Long-term outcomes of corticosteroid graft versus host disease prophylaxis in peripheral blood allogeneic haemopoietic stem cell transplant: a comparative cohort analysis.
2023cited by 1position: contributordoi
PB2697: LONG TERM PEJORATIVE IMPACT OF LENALIDOMIDE MAINTENANCE ON HEALTH-RELATED QUALITY OF LIFE IN CHRONIC LYMPHOCYTIC LEUKEMIA. ANCILLARY STUDY OF THE PHASE III CLL6-RESIDUUM TRIAL
2023cited by 0position: contributor
Persistence of ex vivo expanded tumour and pathogen specific T-cells after allogeneic stem cell transplant for myeloid malignancies (the INTACT study)
2023cited by 0position: contributordoi
Supporting family members requested to donate hematopoietic stem cells to a relative: development and pilot testing of a psycho-educational resource
Journal of Psychosocial Oncology Research & Practice 2023cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Emily Blyth · The University of Sydney15 papers (2013–2023)Kenneth Micklethwaite · The University of Sydney12 papers (2013–2023)Leighton Clancy · Westmead Hospital10 papers (2013–2022) · 10 papers (2020–2026) · 9 papers (2021–2026)Constantine S. Tam · Alfred University6 papers (2019–2025)Renee Simms · Westmead Institute for Medical Research6 papers (2013–2022)David Bishop · The University of Sydney6 papers (2015–2023)Andrew W. Roberts · The University of Melbourne5 papers (2019–2022)Barbara Withers · St Vincent's Hospital Sydney5 papers (2015–2019)Peter J. Shaw · Children's Hospital at Westmead5 papers (2013–2022)Selmir Avdic · Westmead Institute for Medical Research5 papers (2013–2022)Jane Burgess · Westmead Institute for Medical Research5 papers (2013–2021) · 5 papers (2021–2025)Peter J. Shaw · University of Sydney5 papers (2020–2022)Gaurav Sutrave · The University of Sydney4 papers (2017–2022)Rebecca T. Brown · Veterans Health Administration4 papers (2013–2018)Mark Hertzberg · Australasian Leukaemia and Lymphoma Group4 papers (2012–2023)Nicole Gilroy · The University of Sydney4 papers (2012–2023)John F. Seymour · Peter MacCallum Cancer Centre4 papers (2019–2020)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Computational Mechanics · Hematology →